Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Other Non-Current Liabilities: 2022-2024

Historic Other Non-Current Liabilities for Heron Therapeutics (HRTX) over the last 3 years, with Dec 2024 value amounting to $615,000.

  • Heron Therapeutics' Other Non-Current Liabilities rose 1847.72% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year increase of 1847.72%. This contributed to the annual value of $615,000 for FY2024, which is 155.19% up from last year.
  • As of FY2024, Heron Therapeutics' Other Non-Current Liabilities stood at $615,000, which was up 155.19% from $241,000 recorded in FY2023.
  • Heron Therapeutics' Other Non-Current Liabilities' 5-year high stood at $615,000 during FY2024, with a 5-year trough of $241,000 in FY2022.
  • For the 3-year period, Heron Therapeutics' Other Non-Current Liabilities averaged around $365,667, with its median value being $241,000 (2023).
  • Data for Heron Therapeutics' Other Non-Current Liabilities shows a peak YoY skyrocketed of 155.19% (in 2024) over the last 5 years.
  • Over the past 3 years, Heron Therapeutics' Other Non-Current Liabilities (Yearly) stood at $241,000 in 2022, then remained steady at $241,000 in 2023, then soared by 155.19% to $615,000 in 2024.